Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Other Non Operating Income (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Other Non Operating Income for 4 consecutive years, with $57000.0 as the latest value for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 42.5% year-over-year to $57000.0; the TTM value through Dec 2025 reached -$19000.0, down 101.56%, while the annual FY2025 figure was -$19000.0, 101.56% down from the prior year.
  • Other Non Operating Income was $57000.0 for Q4 2025 at Day One Biopharmaceuticals, up from -$34000.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $1.2 million in Q3 2024, with the low at -$34000.0 in Q3 2025.
  • Historically, Other Non Operating Income has averaged $76000.0 across 4 years, with a median of -$10000.0 in 2024.
  • The largest annual shift saw Other Non Operating Income crashed 300.0% in 2023 before it skyrocketed 40000.0% in 2024.
  • Over 4 years, Other Non Operating Income stood at -$26000.0 in 2022, then skyrocketed by 30.77% to -$18000.0 in 2023, then surged by 322.22% to $40000.0 in 2024, then skyrocketed by 42.5% to $57000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were $57000.0 in Q4 2025, -$34000.0 in Q3 2025, and -$19000.0 in Q2 2025.